isnt the off label mooted by the fact that there a
Post# of 148158
in other words, all of cydy's disease-specific patents are as yet unawarded so the uspto 20 year clock is not yet begun?
i think this means that no generic leronlimab can be marketed for at least 20 years, rather than the fda 12 year limit (assuming the fda approved LL for covid today)?